Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23137487 | 0.88 | BRD4 (0.39) | ADORA2AADORA2BADORA1ALDH1A1KDM4E | |
| SCHEMBL28807335 | 0.85 | LCK (0.43) | ADORA2AADORA2BADORA1LCKALDH1A1 | |
| SCHEMBL21901446 | 0.84 | LCK (0.40) | ADORA2AADORA2BADORA1LCKALDH1A1 | |
| SCHEMBL29111201 | 0.84 | CA1 (0.41) | ADORA2AADORA2BADORA1LCKALDH1A1 | |
| SCHEMBL21901580 | 0.83 | LCK (0.45) | LCKBRAF | |
| SCHEMBL21839458 | 0.82 | CA1 (0.40) | ADORA2AADORA2BADORA1LCKALDH1A1 | |
| SCHEMBL24785779 | 0.82 | LCK (0.44) | LCKALDH1A1BRAF | |
| SCHEMBL23496720 | 0.82 | LCK (0.47) | LCK | |
| SCHEMBL21839522 | 0.81 | LCK (0.43) | LCKMAPTBRAF | |
| SCHEMBL28902830 | 0.81 | LCK (0.44) | LCKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| WO-2021052499-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | ADORA2A 3858/4885ADORA2B 2787/4885ADORA1 1981/4885 |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | ADORA2A 3858/4885ADORA2B 2787/4885ADORA1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.